Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.

about

Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.

Item

http://www.wikidata.org/entity/Q49445381

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@en

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@nl

type

Item

label

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@en

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@nl

prefLabel

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@en

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@nl

P1476

Time-Kill Analysis of Ceftoloz ...... from Cystic Fibrosis Patients.

@en

P2093

Henderson D Warnock

http://www.w3.org/2001/XMLSchema#string

Jamie L Wagner

http://www.w3.org/2001/XMLSchema#string

Kayla R Stover

http://www.w3.org/2001/XMLSchema#string

S Travis King

http://www.w3.org/2001/XMLSchema#string

P2860

Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia

Lung infections associated with cystic fibrosis.

Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.

Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.

P2888

s40121-017-0176-8

P304

507-513

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40121-017-0176-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hana Rac

Katie E Barber

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092330443

http://www.w3.org/2001/XMLSchema#string

P698

29058126

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

P932

5700896

http://www.w3.org/2001/XMLSchema#string